Type II DiabetesPhase 1NCT00882882
To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions
A Phase 1 study testing Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC and GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb in people with Type II Diabetes, run by Sandoz.
Trial summary
To demonstrate the relative bioavailability of Metformin HCl 500 mg XR tablets under fasting conditions. Read more about this study
- Who is it for?
- Ages 19 to 49 yearsHealthy volunteers can take part
- Conditions the study is for
- Type II Diabetes
- What is being tested?
- Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC and GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- No sites listed yet
- Study dates
- Jun 2001to Jun 2001
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 49 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Who cannot join
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
About this study
Official title: A Relative Bioavailability Study of Metformin HCL 500 mg XR Tablets Under Fasting Conditions
To demonstrate the relative bioavailability of Metformin HCl 500 mg XR tablets under fasting conditions.
- Conditions
- Type II Diabetes
- Being tested
- Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC, GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Metformin HCL 500 mg Extended-Release Tablets, Geneva PTCDrug
Metformin HCL 500 mg Extended-Release Tablets, Geneva PTCDrug
GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers SquibbDrug
GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers SquibbDrug
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC Receives: Drug: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC |
| 2 | Experimental | Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC Receives: Drug: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC |
| 3 | Active comparator | GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb Receives: Drug: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb |
| 4 | Active comparator | GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb Receives: Drug: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bioequivalence based on AUC and Cmax
Measured: 23 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2009 (estimated)
- Study startJun 2001
- Primary completionJun 2001
- Study completionJun 2001
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type II DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sandoz
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- So Ran Hong, M.D., Principal investigator, Novum Independent Institutional Review Board
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00882882
- Sponsor's protocol ID
- B013701
- Status last verified
- Apr 2009
- First submitted
- 16 Apr 2009
- Last updated
- 29 Mar 2017
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Relative Bioavailability Study of Metformin HCL 500 mg XR Tablets Under Fasting Conditions
- ClinicalTrials.gov ID
- NCT00882882
- Acronym / sponsor ID
- B013701
- Conditions
- Type II Diabetes
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- SandozIndustry (pharma, biotech, devices)
- Study start
- Jun 2001
- Primary completion
- Jun 2001 (actual)
- Study completion
- Jun 2001 (actual)
- First posted
- 17 Apr 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To demonstrate the relative bioavailability of Metformin HCl 500 mg XR tablets under fasting conditions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTCMetformin HCL 500 mg Extended-Release Tablets, Geneva PTC |
| 2 | Experimental | Drug: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTCMetformin HCL 500 mg Extended-Release Tablets, Geneva PTC |
| 3 | Active comparator | Drug: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers SquibbGLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb |
| 4 | Active comparator | Drug: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers SquibbGLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb |
Who may qualify
- Ages
- 19 to 49 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Key exclusion criteria (2 listed)
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC | Drug | 1 |
| Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC | Drug | 2 |
| GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb | Drug | 3 |
| GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb | Drug | 4 |
Primary outcome
Bioequivalence based on AUC and Cmax
Time frame: 23 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Mar 2017.
Related trials for Type II Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
So Ran Hong, M.D. principal investigator
Novum Independent Institutional Review Board
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC and GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb in people with Type II Diabetes, run by Sandoz.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bioequivalence based on AUC and Cmax (time frame: 23 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2017.